Introduction
Invariant natural killer T (iNKT) cells form a subset of regulatory T cells with features of both innate and adaptive immunity. In contrast to conventional T cells that are activated by a peptide presented by an MHC class I or II molecule, iNKT cells recognize lipid derivatives present in the context of CD1d, a non-classical MHC I molecule expressed on antigen presenting cells (APCs) (Godfrey et al, 2004) .
The list of CD1d binding glycolipids that can activate iNKT cells is consistently growing and contains different endogenous and exogenous glycolipids. The latter includes very diverse microbial glycolipids and synthetically derived compounds, of which a-galactosylceramide (a-GalCer) is a prototypical glycolipid antigen. a-GalCer consists of a galactose head group that is a-anomerically linked to a phytoceramide, which is composed of a phytosphingosine chain coupled to an acyl chain. The crystal structures of both mouse and human CD1d bound to a-GalCer show that both alkyl chains fit into two pockets of CD1d, the F 0 and A 0 pocket, while the galactose is exposed at the CD1d surface for interaction with the TCR (Koch et al, 2005; Zajonc et al, 2005a) . The invariant a chain of the TCR recognizes the sugar moiety, whereas the TCR-b chain interacts with CD1d residues. However, in contrast to conventional T cells, the complementarity determining regions of the iNKT TCR do not alter their conformation upon antigen recognition (Borg et al, 2007) and appear to be functionally conserved in both mouse and man (Pellicci et al, 2009) .
In this context, TCR-dependent recognition of a-GalCer results in the robust production of Th1 (e.g., , Th2 (e.g., IL-4) and also Th17 cytokines both by iNKT cells itself and by activated bystander cells (Coquet et al, 2008) . As several pathological processes are characterized by Th1-or Th2-polarized immune responses, much attention has been focused on attempting to skew iNKT cell cytokine responses towards a more Th1-or Th2-biased cytokine profile. Such strategies have been shown to be effective for Th2 analogues such as OCH, which has been shown to improve the outcome of several autoimmune models including experimental autoimmune encephalitis and arthritis (Miyamoto et al, 2001; Chiba et al, 2004) . Conversely, an a-GalCer analogue, in which the oxygen of the glycosidic linkage has been altered to methylene (a-C-GalCer), is known to skew iNKT cell responses towards a Th1 profile and has been applied to the B16 model murine model for melanoma metastasis (Schmieg et al, 2003) .
Although the underlying mechanisms are currently unclear, several groups have attempted to provide models that explain iNKT cell cytokine polarization. For example, for Th2 analogues such as OCH, the analysis of the crystal structure when bound to CD1d shows the absence of an induced fit above the F 0 pocket of CD1d (F 0 roof). This has been proposed to result in a shorter half-life for CD1d-OCH complexes, which may modulate the interaction with the iNKT TCR (Sullivan et al, 2010) . As a consequence, the ability of iNKT cells to activate accessory cell types such as NK cells is also diminished. For other Th2-polarizing analogues, the ability to directly load CD1d on the surface of cellular membranes was proposed (Bai et al, 2009; Im et al, 2009) . Although a-C-GalCer displayed a reduced TCR avidity similar to OCH in vitro, it was shown that the complexes with CD1d were much more stable in vivo, which allowed a more sustained activation of iNKT cells (Sullivan et al, 2010) . This in turn is correlated with its uniquely Th1-biasing properties, such as inducing IL-12 in a CD40L-dependent manner (Fujii et al, 2006) . Additionally, the role of APCs has been emphasized by the observation that loading of bone marrow dendritic cells (BMDCs) with a-GalCer and a-C-GalCer enhances its Th1-polarizing potencies in contrast to its soluble injection (Fujii et al, 2002) . Generally, the currently described Th1-and Th2-biasing a-GalCer analogues, such as a-C-GalCer or OCH, tend to exhibit reduced overall antigenic potencies compared with a-GalCer in vivo. Affirmatively, both a-C-GalCer and OCH have been shown to display a relatively weak interaction with CD1d and TCR. Here, we describe that introduction of selected aromatic groups at position 6 00 of the galactopyranosyl ring may afford analogues with unique functional features, that is, a strong Th1 polarization and tumour suppression. These interesting properties are believed to result from a reinforced interaction with CD1d, caused by the induction of significant conformational changes in CD1d that allows accommodation of the aromatic ring. These findings highlight an hitherto unknown flexibility of CD1d in accommodating glycolipids by inducing the formation of an additional small pocket on top of the A 0 roof, independently of the F 0 and A 0 pockets, leading to more sustained iNKT cell responses in vivo and also broadening the range of glycolipids that can activate iNKT cells.
Results

6
00 -derivatized a-GalCer analogues induce a marked Th1 polarization The crystal structure of the hCD1d-a-GalCer-TCR trimolecular complex highlighted the importance of the 2 00 -OH, 3 00 -OH and 4 00 -OH groups of the galactose head group, as all these hydroxyl groups form strong hydrogen bonds with Gly96a, Ser30a and Phe29a located on the human invariant TCR-a chain (Borg et al, 2007) . The 6 00 -OH group is the only hydroxyl group not involved in hydrogen bond formation, suggesting the possibility of introducing modifications without the loss of important interactions. Therefore, we generated a series of analogues with aromatic groups connected via different linkages to the C6 00 of the galactose group aimed at generating extra hydrophobic interactions. For this study, we selected five novel synthetic glycolipids, structurally related to a-GalCer, comprising the 3-epimer of a-GalCer (xylo-a-GalCer) and four 6 00 -derivatives (NU-a-GalCer, PhU-aGalCer, BzNH-a-GalCer and 4ClBzHN-a-GalCer) (Figure 1 ). Their Th1-Th2 profile was analysed by determining the IFN-g and IL-4 levels in the serum. NU-a-GalCer, featuring a naphthylurea (NU) substituent, induced serum levels of IFN-g comparable to a-GalCer combined with markedly reduced IL-4 levels, thereby inducing the most significant Th1 bias from all the studied 6 00 -derivatives. By contrast, injection with xylo-a-GalCer induces a weak Th2 profile as compared with the conventionally used Th2 polarizer OCH (Miyamoto et al, 2001; Chiba et al, 2004) . Some iNKT cell subsets are known to secrete IL-17 (Coquet et al, 2008) . However, IL-17 secretion was undetectable in the serum at different time points by any of the studied analogues (data not shown). Furthermore, 6 00 -derivatives induced also a Th1 cytokine bias in mice of a BALB/c background (data not shown) and this was CD1d dependent (Supplementary Figure  S2) . Thus, addition of an aromatic moiety at the 6 00 -position of the galactose moiety leads to a marked functional Th1 polarization in vivo.
It has previously been shown that a-GalCer-induced IFN-g production in vivo can be prolonged by loading the glycolipids onto BMDCs (Fujii et al, 2002) . We therefore investigated whether the Th1 profile induced by NU-a-GalCer could be extended when using NU-a-GalCer-loaded BMDCs. As shown in Figure 1B and Supplementary Figure S1 , the IFN-g response to NU-a-GalCer-pulsed BMDCs is markedly higher compared with a-GalCer, leading to a sustained Th1 bias in vivo.
In this context, most iNKT cell-dependent IFN-g production is derived from NK cell activation in an IL-12-dependent manner (Kitamura et al, 1999) . In line with this, IL-12 production was found to be markedly elevated for NU-aGalCer compared with a-GalCer ( Figure 1B ; Supplementary Figure S2 ). Furthermore, NU-a-GalCer was also able to induce a Th1-biased cytokine secretion in cultures of human peripheral blood mononuclear cells (PBMCs) (data not shown) and purified human iNKT cells ( Figure 1C ), highlighting the conserved nature of the Th polarization.
Superior tumour protection of 6
00 -modified analogues Encouraged by the fact that IL-12 and IFN-g are the primary mediators of prevention of lung metastasis in the B16 melanoma model (Kim et al, 2000; Kakuta et al, 2002; Airoldi et al, 2007) , we decided to directly test the in vivo impact of the Th1 bias elicited by NU-a-GalCer. We therefore evaluated whether the Th1 bias elicited by NU-a-GalCer provided an enhanced protection in the B16 melanoma model when compared with a-GalCer or xylo-a-GalCer, a weak Th2-biasing analogue. In this context, the glycolipids were either directly injected or delivered via BMDCs. When administered directly at high doses, all of the tested glycolipids prevented tumour growth (Figure 2A ), whereas at lower doses only NU-a-GalCer, and to a lesser extent a-GalCer, could provide protection (Figure 2A ). When glycolipids were loaded onto BMDCs and adoptively transferred, NU-a-GalCer was significantly more potent in preventing tumour growth compared with a-GalCer and xylo-a-GalCer, the latter eliciting very little if any tumour protection under these conditions ( Figure 2B and C). When the tumour load was doubled the observed differential effect of NU-a-GalCer versus a-GalCer and xylo-a-GalCer was even more striking ( Figure 2D ).
Increased calcium flux and IL-2-dependent NKT cell expansion
To further investigate the anti-tumour potency of NU-aGalCer, we assayed iNKT cell frequency and expansion at several time points after administration of the glycolipidpulsed BMDCs to mice. Consistent with earlier studies, iNKT expansion could be observed 2 days after transfer of a-GalCer-pulsed BMDCs. Strikingly, NU-a-GalCer induced a more prolonged iNKT cell expansion in both spleen and liver (Figure 3 ; Supplementary Figure S3 ). Five days after injection of BMDCs pulsed with NU-a-GalCer, iNKT cell numbers were increased up to 2% of all lymphocytes in spleen and 35% in the liver, representing a nearly six-and two-fold expansion, respectively. To directly evaluate the proliferative capacity of iNKT cells, DNA labelling studies (with BrdU) were performed after adoptive transfer of glycolipid-pulsed BMDCs. Recipients of NU-a-GalCer-pulsed BMDCs had an up to twofold increase in the BrdU incorporation as opposed to mice injected with a-GalCer-loaded cells, indicating a marked increase in iNKT cell expansion ( Figure 3A ). We also assessed the impact on human iNKT cell expansion. Here, purified human iNKT cells were labelled with CFSE and co-cultured with PBMCs that had been loaded with NU-a-GalCer or a-GalCer. As was observed in mice in vivo, NU-a-GalCer induced an increased CFSE dilution and thus proliferation of human iNKT cells when compared with a-GalCer ( Figure 3B ) and this NU-a-GalCer-mediated expansion was dependent upon IL-2 (data not shown). Accordingly upon recognition of the NU-a-GalCer-CD1d complex, iNKT cells produce IL-2 in much higher and sustained quantities than the control glycolipids ( Figure 4A) . Thus, iNKT cell recognition by NU-a-GalCer induces an increased IL-2 secretion as compared with a-GalCer and ultimately results in a stronger, iNKT cell proliferation.
Because IL-2 synthesis is triggered by TCR mediated recognition of antigens and subsequent increase of intracellular calcium levels, we focused on calcium flux elicited by iNKT cells after recognition of the glycolipid/CD1d complex. The role of calcium-dependent signals has not been extensively studied in the context of iNKT cells, although it was suggested to be correlated with the formation of a more stable immunological synapse (McCarthy et al, 2007) and activation of additional cytokine production (Wang et al, 2008) . To directly evaluate the impact of the C6 00 -modification, we measured intracellular calcium concentration by video microscopy. As indicated in Figure 4 , the higher IL-2 production by NU-a-GalCer versus a-GalCer was associated with a marked increase in both the frequency of calcium signalling cells and the calcium signal peak (see also Supplementary videos 1-4).
Differential calcium fluxes elicited by glycolipid ligands may be directly related to a different binding stability of the CD1d-glycolipid-T-cell receptor (McCarthy et al, 2007) . We therefore focused on the molecular interaction of NU-a-GalCer with mCD1d and the iNKT TCR by surface plasmon resonance (SPR) and crystallography. For comparative purposes, we included the prototypical Th1 analogue a-C-GalCer, as well as the synthetic analogue BnNH-GSL-1 0 . The latter also possesses an aromatic moiety, which, however, is linked to the sugar via an amide (5 00 -CO-NH-) linkage. In that respect it may be considered as an amide derivative of GSL-1 0 , a galacturonic acid congener of a-GalCer isolated from Sphingomonas species (Kinjo et al, 2005) . BnNH-GSL-1 0 is also a Th1 polarizer, however, it has a weaker profile as it induces both less IL-4 and IFN-g compared with NU-a-GalCer (Supplementary Figure S4 ).
Biochemical characterizations
We measured the equilibrium binding constants of the refolded Va14Vb8.2 TCR towards the a-GalCer analogues Figure 4 NU-a-GalCer induces a stronger iNKT cell response when bound to bone marrow-derived dendritic cells (BMDCs). BMDCs were grown with GM-CSF for 10 days and subsequently loaded with a glycolipid (100 ng/ml) for 2 h. (A) Co-culture with an iNKT cell line (2C12) was set up for 16 h and IL-2 production was measured by ELISA. Xylo-a-GalCer, NU-a-GalCer and DMSO significantly differ from a-GalCer (twotailed Mann-Whitney U-test). Data are shown as mean with s.e.m. (n ¼ 5). One representative experiment of two independent experiments. (B) The iNKT cell line (2C12) was loaded with FURA-2 and added to glycolipid-pulsed BMDCs. Five minutes later, calcium signals in iNKT cells were measured using epifluorescence microscopy. On average, about 50 cells were monitored for 10 min. An increase of fluorescence of about 10% was determined as a cell displaying an increase in intracellular calcium concentration. The percentage of increase was normalized to 100% for a-GalCer. NU-a-GalCer induced more cells to increase their calcium concentration. Representation of pooled data from four independent experiments. (C) Peak value of transient calcium changes expressed as ratiometric FURA-2 measurements. NU-a-GalCer displays higher increases in calcium concentration compared with a-GalCer. Every dot represents a cell displaying a calcium transient. Data are shown as mean with s.e.m. Four similar experiments were performed. NU-a-GalCer, a-C-GalCer and BnNH-GSL-1 0 bound to mouse CD1d by SPR (Supplementary Figure S1) . With an equilibrium binding constant (K D ) of 39.6 nM, the TCR-binding affinity towards NU-a-GalCer is slightly weaker than to a-GalCer (11.2 nM) , while both BnNH-GSL-1 0 and a-C-GalCer are much weaker than a-GalCer (K D of 187 and 247 nM, respectively) but higher in affinity than the bacterial antigen GalA-GSL aka GSL-1 0 (K D ¼ 0.7 mM) . In summary, the kinetic data indicate that the initial binding of the TCR to all four mCD1d-glycolipids complexes is very similar. This suggests that their binding to CD1d before TCR engagement is similar, in contrast to microbial antigens that bind differently to mCD1d before TCR engagement and, therefore, have a different TCR association rate . As a result, the chemical differences between the analysed glycolipids are mostly affecting the dissociation rate, and thus the stability of the CD1d-glycolipid-TCR complexes.
Crystal structures of the TCR complexes
To elucidate the structural details of the mCD1d-NU-aGalCer-TCR interaction and to understand how the relatively large 6 00 -naphthylurea substituent can be accommodated between the mCD1d-TCR interface without a significant reduction in TCR-binding affinity, we crystallized the TCR-NU-a-GalCer-mCD1d complex and determined the structure to 2.3 Å resolution ( Figure 5 ; Supplementary Table S1 ). For comparison, we have also determined the crystal structures of the mCD1d-a-C-GalCer-TCR complex, as well as the Figure 5 Stereoview of the electron density for the different mCD1d-bound glycolipids. The 2Fo-Fc electron density map is contoured at 1s and shown as a blue mesh around the glycolipid ligands NU-a-GalCer (A), BnNH-GSL-1 0 (B) and a-C-GalCer (C) in a side view. Several hydrophobic mCD1d residues interacting with the lipids are depicted. Note that the electron density for the phenyl moiety of BnNH-GSL-1 0 that is exposed into the solvent is rather poor, indicating a slight disorder, which stems from lack of defined contacts with either CD1d or TCR residues. mCD1d-BnNH-GSL-1 0 -TCR complex to 2.9 and 2.25 Å , respectively. Each structure contains one ternary complex in the asymmetric unit of the crystal and exhibited very clear electron density for each of the glycolipid ligands after molecular replacement, which allowed for unambiguous fitting of the glycolipid ligand ( Figure 5 ).
Similar to a-GalCer, all three glycolipids are bound with their phytosphingosine chain inserted in the F 0 pocket and the long-chain fatty acid in the A 0 pocket, where it encircles the A 0 pole (Cys12-Phe70) in the typical anti-clockwise orientation, when looked upon from the top of the binding. The a-linked galactose moieties are similarly exposed at the CD1d binding grooves for TCR recognition. Strikingly, the 6 00 -naphthyl ring that distinguished NU-a-GalCer from a-GalCer sits above the A 0 pole, but faces down into a small binding pocket formed by induced fit (see later), rather than being exposed into the solvent, where it could interfere with TCR binding.
TCR docking and ligand recognition
Overall, the TCR adopts a docking mode nearly identical to the recently determined TCR-a-GalCer-mCD1d complex directly above the F 0 pocket of mouse CD1d ( Figure 6A ; Supplementary Figure S5 ; Pellicci et al, 2009) . In all ternary complex structures, TCR contacts with mCD1d are dominated mainly by the CDR2b and CDR3a loop, similar as observed in the TCR-a-GalCer-mCD1d complex. However, due to the usage of a different CDR3b rearrangement (CASGDEGYTQYF), which results in a 3-amino acid shorter CDR3b loop compared with the Va14Vb8.2 TCR used in the a-GalCer complex (CASGDAGGNYAEQFF), additional contacts are formed between CDR3b and mCD1d in the NU-a-GalCer, a-C-GalCer and BnNH-GSL-1 0 complex structures (Supplementary Figure S5) . CDR3b, which is disordered in the ternary structure of the TCR-a-GalCer-mCD1d complex (Pellicci et al, 2009) , is well ordered in our three structures and exclusively forms both van der Waals interactions, as well as one salt bridge interaction through Asp96b with Lys148 on the a2 helix of mCD1d (the latter only for NU-a-GalCer and BnNH-GSL-1 0 ) (Supplementary Figure S5) . The galactose moiety of each glycolipid is exposed for recognition by the TCR. The contacts between the TCR and NU-a-GalCer are exactly the same as those observed between the TCR and a-GalCer. Specifically, the 2 00 -OH group of the galactose ring forms an H-bond with Gly96 of CDR3a and the 3 00 -and 4 00 -OH groups of the galactose form H-bonds with Asn30 of CDR1a loops of TCR. The 3-OH of the sphingosine chain also form hydrogen bonds to Arg95a of CDR3a ( Figure 6B ). However, both BnNH-GSL-1 0 and a-C-GalCer form only three instead of four H-bonds with the TCR. In BnNH-GSL-1 0 , the galactose is tilted slightly downward into the CD1d groove, moving the 4 00 -OH of the galactose away from the Asn30a. a-C-GalCer loses an H-bond between R95a of the TCR and the 3-OH of the phytophingosine chain, due to a slight rotation of the ceramide backbone. As a consequence, the TCR interaction with NU-a-GalCer is comparable to a-GalCer, while both BnNH-GSL-1 0 and a-C-GalCer form less stable interactions, which is in agreement with the observed increase in TCR dissociation rates.
Ligand binding and induced fit in CD1d
Binding of NU-a-GalCer to mCD1d parallels that of a-GalCer. All hydrogen bond interactions that were described for Figure 6 Binding comparison of NU-a-GalCer, BnNH-GSL-1 0 and a-C-GalCer with a-GalCer. (A) Overview of the mCD1d-NU-a-GalCerVa14Vb8.2 TCR ternary complex. (B) Binding of the TCR (cyan) to the glycolipids NU-a-GalCer (yellow), BnNH-GSL-1 0 (green) and a-C-GalCer (salmon), which are superimposed onto a-GalCer (thin cyan sticks, from PDB ID 3HE6) for comparison. Hydrogen bond interactions are indicated with blue dashed lines. (C) H-bonds between the glycolipids and CD1d are conserved, however, an additional conserved H-bond between the carbonyl oxygen of NU-a-GalCer and BnNH-GSL-1 0 with Thr159 of CD1d is formed (red dashed lines), resulting in a tilt of the BnNH-GSL-1 0 galactose. Also, a-C-GalCer 3 0 -OH of galactose forms an additional 3.5 Å H-bond with the backbone amide of Thr156, while losing the glycosidic H-bond (middle row). Bottom row illustrates H-bond interactions between glycolipids and mCD1d from a TCR view. a-GalCer involving the 2 00 -and 3 00 -OH of the galactose and the 3-and 4-OH of the ceramide backbone with CD1d residues Asp80, Asp153 and Thr156, are also conserved in the NU-a-GalCer structure ( Figure 6C ). In addition, NU-aGalCer forms an additional H-bond between the carbonyl oxygen of the urea linker that connects the galactose and the naphthyl moieties. Interestingly, the same H-bond is also formed between the carbonyl oxygen of BnNH-GSL-1 0 , however, as this carbonyl is in closer proximity to the galactose, the formation of that interaction pulls the galactose down towards CD1d and away from the TCR. This results in the aforementioned loss of one H-bond with the TCR (Figure 6B and C) . a-C-GalCer cannot form the H-bond between the a-anomeric oxygen and Thr156, as the oxygen is replaced by carbon, instead it forms a novel H-bond between the 2 00 -OH of galactose with the backbone oxygen of Thr156 ( Figure 6C) .
The most striking difference between NU-a-GalCer and a-GalCer, BnNH-GSL-1 0 or a-C-GalCer is the aforementioned induced fit in CD1d. In order to accommodate the naphthyl group of NU-a-GalCer between the a1 and a2 helices of CD1d both helices are opened laterally by about 1.3 Å . The distance between the backbones of Met69 (a1 helix) and Thr159 (a2 helix) of CD1d is increased from 9.2 to 10.5 Å ( Figure 7A ). In addition, the side chain of Met69, which is involved in the formation of the A 0 roof, adopts a different conformation, thereby creating a narrow hydrophobic cleft formed by Leu66, Met69, Phe70 and Leu163 on top of the A 0 roof, in which the aromatic substitution is nicely accommodated ( Figure 7B ). The binding of the aromatic group in this pocket forms a third anchor in addition to the two more deeply inserted alkyl chains, thus increasing the van der Waals interactions between ligand and CD1d. We have qualitatively assessed the mCD1d-glycolipid stability in a modified SPR assay using an a-GalCer-specific antibody to monitor loss of binding to CD1d due to dissociation of glycolipid from CD1d ( Figure 7C ). NU-a-GalCer exhibits much more interactions with CD1d (117 vdw and 8 H-bond interactions, 1150 Å 2 interface surface) than with a-GalCer (95 vdw, 7 H-bonds, 1027 Å 2 interface surface) leading to a slightly increased binding affinity of NU-a-GalCer to CD1d as compared with a-GalCer (Supplementary Table S2 ; Figure 7C ). The slightly increased CD1d binding stability of NU-a-GalCer compared with a-GalCer is in general agreement with the roughly 10% increase in both buried surface area and contacts formed between lipid and mCD1d. The NU linker also pulls the galactose slightly down into the groove, similar but far less pronounced than observed for BnNH-GSL-1 0 . This results in slightly less intimate packing against Pro28 of the TCR CDR1a (not shown) and an increased distance of the H-bond between 4 00 -OH of NU-a-GalCer and Asn30 of the TCR, which could be the reason for the 2-3 faster TCR dissociation compared with a-GalCer. Thus, NU-a-GalCer induces marked structural changes in CD1d, that are strictly dependent upon the addition of aromatic moiety with judiciously chosen linker length, as shorter linkers result in exposure of the aromatic ring into the solvent, as seen for BnNH-GSL-1 0 .
Discussion
Our results provide new insights into the mechanisms controlling TCR responses to glycolipids by showing that addition of aromatic groups at the galactose part of a-GalCer can lead to an additional binding pocket of mCD1d through an induced fit mechanism. This in turn slightly enhances the affinity of the glycolipids for CD1d leading to a more sustained interaction with the iNKT TCR and lowers thresholds for iNKT cell activation. This is accompanied by skewed under constant flow of running buffer was monitored after 18 h. Note that under these conditions, slightly more NU-a-GalCer remains bound to CD1d compared with a-GalCer, indicating increased CD1d-lipid stability, while a-C-GalCer dissociates much faster from mCD1d. The experiment was performed twice and also carried out using 0.5% Tween-20 (not shown), which indicated a similar trend. cytokine patterns, providing an additional and previously unappreciated mode of modulating iNKT cell responses. This is in sharp contrast to MHC I or II binding where no formation of additional pockets has been reported upon peptide binding, although there is a dynamic interaction between peptide and MHC that can affect the conformation of the a2 helix at the position where it forms the typical kink (Borbulevych et al, 2009) . Additionally, previous studies on conformational changes of CD1d are scarce and limited to the F 0 pocket. It was shown previously that binding of a-GalCer to CD1d results in an induced fit above the F 0 pocket, leading to the formation of the F 0 roof. To date, a-GalCer is the only lipid that can form the F 0 roof before TCR binding, while in two previously determined complex structures with microbial antigens the F 0 roof is formed only after TCR binding, likely through the hydrophobic finger L99 of TCR CDR3a 0 . We previously proposed the formation of the F 0 roof to be a key determinant in modulating the TCR affinity, especially the TCR off-rate . Earlier studies proposed that the F 0 pocket could also partially collapse when containing short-chain lipids, such as OCH (McCarthy et al, 2007) , which would alter the F 0 roof and change the TCR recognition surface. However, both the mCD1d-OCH binary structure as well as the more recent mCD1d-OCH-TCR ternary structure (Wun et al, 2011) do not reveal such gross structural changes because of the presence of a spacer molecule in the remainder of the F 0 pocket (Sullivan et al, 2010) . Thus, the ability to form the F 0 roof is important in modulating TCR affinities, with highest affinities for those ligands that can pre-form the F 0 roof upon binding to CD1d, while a partial collapse of the F 0 pocket when shorter lipids are bound is unlikely. Conformational changes induced by modifying the sugar part of the glycolipid, however, are not yet known, nor has a major induced fit been seen upon glycolipid binding for any other region of CD1d besides the F 0 pocket, nor any other ligand besides a-GalCer or possibly its analogues. Thus, our study reveals a previously unappreciated flexibility of CD1d that can be further exploited for the design of synthetic glycolipid ligands that enhance the binding affinity towards CD1d without disrupting the TCR-binding interface.
Efficient iNKT cell activation is requisite for providing subsequent anti-tumour immunity. This is exemplified by the key roles assigned to Th1-polarizing cytokines such as IFN-g and IL-12 produced by dendritic cells, macrophages and NK cells that arise downstream of iNKT cell activation (Wesley et al, 2005) . Most of the current studies involving Th1-polarizing glycolipids focus on a-C-GalCer (Schmieg et al, 2003; Fujii et al, 2006) , which features a stabilized glycosidic bond. By contrast, here we report on the physiological effects of a group of strong Th1-polarizing analogues characterized by alterations at the 6 0 -position of the galactose. In contrast to what is observed for the a-C-GalCer, both the expansion of the iNKT cell pool and cytokine production in response to these glycolipids were very conserved between men and mice. Additionally when loaded on BMDCs NU-aGalCer was markedly more potent than a-GalCer in preventing the growth of B16 tumours. Although several types of structural modification of the galactose moiety of a-GalCer may lead to Th1 bias, this is generally at the expense of the overall antigenic potency. Strikingly, the absolute cytokine levels for IFN-g and IL-12 achieved by NU-a-GalCer in vivo seem to equal or surpass the levels measured by a-GalCer, yet Th2 cytokines are markedly lower. Although it has been suggested that loading of Th1-polarizing analogues onto CD1d occurs primarily within endosomal compartments (Bai et al, 2009; Im et al, 2009) , APC lacking the cytoplasmic tail of CD1d (therefore, they are not able to load endosomal glycolipids onto CD1d) was able to present NU-a-GalCer (data not shown), suggesting there may be an alternate mechanism for the observed Th1 polarization.
To understand the structural basis of observed functional differences, X-ray crystallographic studies were undertaken in which a-C-GalCer and NU-a-GalCer were compared with aGalCer. Surprisingly, NU-a-GalCer showed much more interaction with CD1d than with a-GalCer, which is primarily caused by formation of an induced fit above the A 0 pocket between Met69 and Thr159. The resulting hydrophobic pocket is perfectly suited in both shape and hydrophobicity to bind the naphthyl group of NU-a-GalCer as a third anchor, in addition to the A 0 and F 0 pockets. The importance of the pocket formation in the strong Th1 polarization was further substantiated by the crystal structure with BnNH-GSL-1 0 , a weaker Th1-polarizing analogue, which exhibits a shorter linker to the phenyl ring and bears the carbonyl group immediately next to the sugar ring instead of two bonds further as in NU-a-GalCer. Both carbonyl atoms form an extra H-bond to Thr159 from the a2 helix of CD1d. However, the Hbond of BnNH-GSL-1 0 leads to a noticeable tilt of the galactose due to the shorter linker and, hence, reduced TCR affinity. NU-a-GalCer recapitulates both an optimal overall linker length to induce the formation of the third small anchor pocket, as well as the correct spacing between the carbonyl oxygen and the galactose to form the conserved Hbond with Thr159 without significantly affecting the galactose orientation. Thus, a conceptual new model has arisen in which additional aromatic groups can interact with CD1d.
Structural changes have so far only been observed around the F 0 pocket of CD1d where they enhance the surface area that is contacting the TCR. In the case of NU-aGalCer, the induced fit above the A 0 pocket results in increased hydrophobic interactions between glycolipid NU-aGalCer and CD1d, which, together with the additional hydrogen bond, likely enhance the stability and half-life of the CD1d-NU-a-GalCer complex. The widening of the helices and the alternate side chain conformation of Met69 suggests that the CD1d binding groove has the potential to structurally adapt to accommodate different functional groups of aGalCer derivatives. Thus, although no CD1d polymorphisms have been described, our results illustrate the existence of another mechanism to accommodate distinct antigens. However, as the TCR-BnNH-GSL-1 0 -mCD1d structure reveals, those modifications have to be connected to the galactose with a judiciously chosen linker length, since shorter linkers likely result in exposure of the aromatic ring into the solvent. This new mode of structural modification of CD1d therefore broadens the spectrum of glycolipids that can stimulate iNKT cells and may facilitate the design of a new spectrum of glycolipid antigens to bind and stimulate iNKT cells. This highlights a delicate balance between the structure-function relationship of CD1d-glycolipid-iNKT TCR complex.
Despite its well-recognized Th1-biasing profile, a-C-GalCer differs substantially from NU-a-GalCer by a number of biochemical and structural properties. Despite a similar initial binding of the TCR, the dissociation rate, and thus the stability of the CD1d-glycolipid-TCR complexes is markedly lower. This is in line with an earlier reported weak TCR stimulus. The underlying structural basis has been unveiled here by the crystallographic structure, which showed that a-C-GalCer forms only three instead of four H-bonds with the TCR. In addition, a-C-GalCer cannot form the H-bond between the a-anomeric oxygen and Thr156, as the oxygen is replaced by carbon, instead it forms a novel H-bond between the 2 00 -OH of galactose with the backbone oxygen of Thr156. Even though the interaction between a-C-GalCer, CD1d and iNKT TCR are weaker than a-GalCer, it is characterized by long-lived, functional complexes on the surfaces of APCs in vivo (Sullivan et al, 2010) . In this context, it should be highlighted that the C-glycoside variant of a-GalCer was designed to provide additional biochemical stability in order to prevent degradation by O-glycosidase enzymes. This may result in increased stability of a cell-associated pool of a-C-GalCer and as such allow continuous replenishment of cell surface complexes. Thus, distinct modes of modifying the interaction between CD1d-glycolipid-iNKT TCR complex exist that affect the functional outcome of glycolipid reactive T cells.
Overall, these findings highlight the previously unexploited flexibility of CD1d in accommodating galactosemodified glycolipids by providing an additional binding pocket of mCD1d through an induced fit mechanism. We speculate that these glycolipids may be useful targets for inducing, superior and more sustained iNKT cell responses in vivo. Whether a similar induced fit mechanism is also utilized by microbial antigens including alternate modifications such as additional fatty acids is an interesting question to be explored.
Materials and methods
Synthetic glycolipids
Glycolipids were synthesized in the Laboratory of Medicinal Chemistry (Trappeniers et al, 2008) and at the Department of Chemistry, Hunter College/CUNY (Schmieg et al, 2003) . OCH and a-C-GalCer were kindly provided M Tsuji (Aaron Diamond AIDS Research Center, NY, USA) and the NIH Tetramer Core Facility. Lyophilized glycolipids were dissolved in pure DMSO (Sigma) at 10 mg/ml concentration and stored at À201C. Glycolipids were solubilized by adding PBS (Invitrogen) or vehicle (96 mg/ml sucrose, 10 mg/ml sodium deoxycholate, 0.05% Tween-20), warming to 801C for 20 min, sonication for 10 min.
Recombinant protein expression and purification
Mouse CD1d-b2-microglobulin (b 2 M) heterodimeric protein was expressed and purified using the baculovirus expression system as reported previously (Zajonc et al, 2005b) . TCR refolding and purification was carried out as reported previously . Pure TCR was stored in Superdex S200 running buffer (50 mM Hepes, 150 mM NaCl pH 7.4) until further use.
Glycolipid loading and NU-a-GalCer-mCD1d-TCR complex formation Lipids NU-a-GalCer, BnNH-GSL-1 0 and a-C-GalCer were dissolved in DMSO at 1 mg/ml. Before loading, 60 ml of each glycolipid solution was diluted to 0.25 mg/ml with 60 ml vehicle solution (50 mM TrisHCl pH 7.0, 4.8 mg/ml sucrose, 0.5 mg/ml sodium deoxycholate and 0.022% Tween-20) and 120 ml of 10 mg/ml Tween-20. The diluted glycolipids were heated in a bath at 801C for 20 min and cooled at room temperature for 5 min. Glycolipids were loaded onto mCD1d by incubating 400 ml mouse CD1d (2.5 mg/ml) overnight with 240 ml pre-heated glycolipid solution (molar ratio of protein to lipid is 1:3) and 800 ml buffer (50 mM Tris-HCl pH 7.0).
For CD1d-TCR complex formation, the refolded TCR was incubated at room temperature for 30 min with lipid-loaded mCD1d at a ratio of 1:2 molar ratio for NU-a-GalCer and BnNH-GSL-1 0 and 1:3 for a-C-GalCer, as the NU-a-GalCer loading efficiency is only 40-50% (measured using the a-GalCer-specific antibody L317 in a modified SPR experiment) and we expected even lower loading efficiencies for a-C-GalCer. The ternary mCD1d-lipid-TCR complexes were isolated from uncomplexed mCD1d and TCR by size exclusion chromatography using Superdex S200 10/300 GL (GE Healthcare) for crystallization.
SPR studies SPR studies were conducted using a Biacore 3000 (Biacore) as reported previously . The lipids were loaded to biotinylated birA-tagged mCD1d in the same way as non-birAtagged mCD1d. In all, 300-500 response units (RU) of mCD1d-glycolipid complexes were immobilized onto a streptavidin sensor chip (Biacore) surface by injection at 5 ml/min (10 mM HEPES, 150 mM NaCl, 3.0 mM EDTA, pH 7.4). A reference surface was generated in another flow channel with unloaded mCD1d immobilized at RU of 500. During the association phase, a series of increasing concentrations of TCR in duplicate were injected for 3 min and the dissociation phase initiated by passage of running buffer alone was continued over 30 min. Experiments were carried out at 251C with a flow rate of 30 ml/min and performed at least two to three times, each time with a different batch of TCR preparation. Kinetic parameters were calculated after subtracting the response to mCD1d molecules in the reference channel, using a simple Langmuir 1:1 model in the BIA evaluation software version 4.1. One representative sensorgram for each lipid is shown.
CD1d-glycolipid stability assay
The assay was modified from previous work (Sullivan et al, 2010) to control for loss of proper folding of mCD1d over the course of the experiment. The lipids a-GalCer, NU-a-GalCer and a-C-GalCer were loaded to biotinylated mCD1d as mentioned above. In all, 1000-2000 RU of each mCD1d-lipid were immobilized on a streptavidin sensor chip (GE Healthcare). A reference surface was generated in another flow channel with unloaded mCD1d immobilized at 1500 RU. The percentage of correctly folded CD1d on the chip at the beginning and at the end of the experiment was measured with a conformation-specific anti-mouse CD1d antibody (clone 1B1, BD Biosciences). The binding of a saturating concentration (1 mM) of the a-GalCer-specific L317 antibody was used to monitor the stability of mCD1d-lipid complexes over time while flowing buffer with a high detergent content (10 mM HEPES, 150 mM NaCl, 3.0 mM EDTA, pH 7.4, 0.2% Tween-20, 30 ml/min) to assist extraction of the lipid from the CD1d binding groove. Binding responses after 18 h were normalized against the initial RU reading and corrected for the amount of folded CD1d still present on the surface, as measured with the 1B1 antibody.
Crystallization and structure determination
Detailed methods are available in the online supplementary material.
Cell lines
The murine iNKT hybridoma N38-2C12 (Va14Vb8.1/8.2b) was provided by L Brossay (Burdin et al, 1998 ) (Brown University, Providence, RI, USA). Cells were cultured in DMEM (Sigma) supplemented with 10% fetal calf serum (Invitrogen), 1% glutamin (Sigma), 1% penicillin streptomycin (Sigma) and 2-mercaptoethanol (Sigma) (called cDMEM hereafter).
Isolation and expansion of BMDCs
BMDCs were isolated from the mouse bone marrow as described previously (Lutz et al, 1999) . Mice C57BL/6 mice were in house bred (in accordance with the general recommendations for animal breeding and housing) or purchased from the Harlan Laboratory, Ja18-knockout and CD1d-knockout mice on the C57BL/6 background were kindly provided by M Taniguchi (Cui et al, 1997) (RIKEN, Tsurumi, Yokohama, Japan) and L Van Kaer (Mendiratta et al, 1997) (Vanderbilt University School of Medicine, Nashville, TN, USA), respectively. Experiments were conducted according to the guidelines of the Ethical Committee of Laboratory Animals Welfare of Ghent University. Mice used for experiments were between 5 and 12 weeks old.
In vitro and in vivo activation of iNKT cells
For in vitro stimulation, murine iNKT hybridoma cells at 5.10E4 cells/well in 96-well plates were stimulated with the 10E5 cells/well glycolipid-pulsed BMDCs in cDMEM for 16 h at 371C, and levels of murine IL-2 secretion were determined by ELISA.
For in vivo activation of iNKT cells, C57BL/6 mice were either intraperitoneally injected with 5 mg glycolipid (dissolved in PBS) or intravenously with 6.10E5 or 1.10E4 glycolipid-pulsed BMDCs.
Calcium level analysis in iNKT hybridoma 2C12 cells were loaded with the calcium-sensitive probe Fura-2 AM (15 mM) (Sigma) for 1 h at 371C in PBS in the presence of pluronic acid (1.5 ml) (Molecular Probes), followed by 30 min deesterification at room temperature and added to glycolipid-pulsed BMDCs (1.4 Â 10E6 cells/ml), grown on 35 mm glass bottom culture dishes (MatTek). Five minutes after start co-culture cytoplasmic-free calcium was monitored with epifluorescence microscopy and digital imaging. Cells were viewed with an inverted epifluorescence microscope (Nikon Eclipse TE300, Analis, Ghent, Belgium) using a Â 40 oil immersion lens (CFI Plan Fluor, Nikon) as previously described (De Vuyst et al, 2009 ).
Isolation of human PBMCs and iNKT cells
PBMCs from healthy adult individuals (n ¼ 5) were isolated by Ficoll density centrifugation (Histopaque, Sigma diagnostics). PBMC was pre-treated with FcR Blocking Reagent (Miltenyi Biotec) for 10 min before incubation with fluorochrome-conjugated mAbs directed against human TCRVa24 (clone C15-PE) and TCRVb11 (clone C21-FITC) and 7-AAD (all from BD) for 30 min. Subsequently, Va24 þ Vb11 þ 7-AAD-cells were single cell sorted in 96-well plates using a FACSAria II (BD). iNKT cells were cultured in the presence of irradiated autologous PBMC (10E5), pre-loaded with glycolipids for 18 h, in RPMI 1640 media supplemented with 10% fetal bovine serum, 1% sodium pyruvate, 1% non-essential amino acids and 1% penicillin/streptomycin (all from Invitrogen) containing 5 U/ml IL-2 (Roche).
For proliferation assays, 10E4 iNKT cells were labelled with CFSE (1 mM) and stimulated with glycolipid-loaded irradiated autologous PBMC (10E5), in the presence of IL-2 (0.1 U/ml). At day 7, cells were harvested and labelled with 6B11 (eBioscience) and 7-AAD to gate out dead cells. CFSE dilution was measured by flow cytometry. Supernatants were collected and used for cytokine measurements by ELISA or CBA assays.
Isolation of murine lymphocytes
Spleen and liver cells were isolated as previously described (Franki et al, 2006) . Lymphocytes were isolated at the interface and washed and resuspended in staining buffer containing saturating amount of anti-Fcg Receptor type II/type III monoclonal antibodies (Miltenyi Biotec, Sunnyvale, CA). PE-labelled CD1d/a-GalCer tetramers were added at room temperature, 15 min before the addition of TCRb (H57-597, eFluor 780, eBioscience) during 30 min on ice. For proliferation analysis, cells were fixed, permeabilized and incubated with DNAse (Sigma) and stained with anti-BrdU (BD). Live cells were acquired on a FACSCanto (BD) flow cytometer and analysed using FlowJo (Tree Star) software.
Statistical analysis
The statistical test used throughout this study was Kruskal-Wallis test with Dunn's multiple comparison test or Mann-Whitney U-test (unpaired, two-sided). Data were analysed using Excel (Microsoft) and Graphpad Prism 5.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
